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We investigate in vitro fibrillation kinetics of the hormone peptide glucagon at various concentra-
tions using confocal microscopy and determine the glucagon fibril persistence length 60µm. At all
concentrations we observe that periods of individual fibril growth are interrupted by periods of sta-
sis. The growth probability is large at high and low concentrations and is reduced for intermediate
glucagon concentrations. To explain this behavior we propose a simple model, where fibrils come
in two forms, one built entirely from glucagon monomers and one entirely from glucagon trimers.
The opposite building blocks act as fibril growth blockers, and this generic model reproduces exper-
imental behavior well.
PACS numbers: 87.14.E-, 87.14.em, 87.64.mk, 87.15.A-
Misfolding and aggregation of peptides and proteins
into fibrils are the hallmarks of around 40 human dis-
eases [1, 2]. Understanding the fibrillation process of one
protein may provide a generic mechanistic insight useful
for understanding fibrillation of a class of proteins. In
this paper we focus on the protein glucagon, which is
a 29 amino acid residue hormone peptide, that upregu-
lates blood sugar levels. It is an important pharmaceu-
tical molecule, which is used to treat diabetic patients
in situations of acute hypoglycemia [3, 4]. As obesity
and the number of diabetic patients is increasing, this
drug becomes more and more relevant. The active state
of glucagon is the monomer, but during pharmaceutical
production the peptide has a high tendency to misfold
and aggregate into fibrils devoid of biological function
[5]. When glucagon is solubilized, it can be found in two
states, which produce glucagon fibrils of different mor-
phologies. Below a concentration of 1 mg/mL, glucagon
is predominantly found in an unstructured monomeric
state, while above 1 mg/mL glucagon form associated
states such as trimers and other oligomers [6–10]. The
monomer and oligomer precursor states lead to twisted
and non-twisted fibrils, respectively [11–13]. Experi-
ments suggest that at high glucagon concentrations, the
monomeric species are not incorporated into fibrils [10]
and the growth of twisted fibrils is inhibited [12].
Fibrillation of proteins and peptides is typically fol-
lowed in bulk using the fibril-binding fluorescent dye
Thioflavin T (ThT). While ThT-based fibrillation kinet-
ics can provide highly valuable information on the mech-
anisms of fibrillation [14], studies of the growth of in-
dividual fibrils can also yield important insights. This
information is provided by techniques such as Total In-
ternal Reflection Fluorescence Microscopy (TIRFM) and
Confocal Microscopy (CM). In TIRFM the observation
depth is ∼150 nm while with CM it is ∼500 nm.
Previously, we have studied growth of individual
glucagon fibrils in real-time using TIRFM [15] at one
fixed glucagon concentration. In that study, fibril growth
was found to be interrupted by periods of stasis, and
the statistics of growth and stasis durations were well
described by a Poissonian process. This dynamic be-
haviour was denoted stop-go kinetics. Switching rates
between the growing and arrested states suggested the
probability of being in the growing state to be ∼1/4. To
explain this value, a Markovian four-state model of fib-
ril growth was proposed. The model predicted that the
growth probability is independent of the glucagon con-
centration. This is in contrast to our findings since here
we demonstrate that the fibril growth probability does
depend on the glucagon concentration.
Here we significantly expand our previous work [15] by
monitoring fibril kinetics over a wide range of glucagon
concentrations. The advantage of this approach is that it
allows us to sample conditions spanning different precur-
sor states of glucagon, i.e. monomers or trimers, lead-
ing to twisted or straight fibrils, respectively. Fibrils
were labeled with the fluorescent dye ThT and moni-
tored using a confocal microscope with an Argon laser.
On freshly plasmated glass plates we observed a volume
of ∼40×40×0.5 µm3. For each of the five different initial
glucagon concentrations (1.5, 3, 6, 10 and 15 mg/mL), a
minimum of two experiments were conducted in aqueous
buffer (50 mM glycine HCl, pH 2.5). The time inter-
val between captured frames was 3.3 mins and the to-
tal observation time of each experiment was about three
days. When fibrils grew along the surface we tracked
their length as a function of time. Sample images of real
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Figure 2.3.27: Persistence length of fibrils from all experiments combined is found
to be (60 +/- 2) µm. Except for two outliers of length ∼11 µm, the fit is of
excellent quality over the complete range of fibril lengths.
2.4 Summary and Suggestions for further Ex-
periments
In this chapter glucagon was introduced and its importance as a pharmaceutical
product motivated a study of its fibrillation properties. Confocal microscopy com-
bined with the fluorophore ThT yielded images in which individual fibrils could be
tracked over time. The tracks were analysed to find the distributions of length and
growth speed and it was shown that fibril growth follows a “stop and go” pattern
where periods of growth are interrrupted by periods of arrest. It was shown that
fibril length could seem to follow a lognormal distribution, but also that this was
probably not caused by cooperative effects in the growth mechanism. The time
development of average fibril length was found and compared to previous studies in
which a saturating average was attributed to fibril breakage, but it was found that
here the saturating average was caused by the entrance of new fibrils rather than
breakage of existing ones. Extremely long or fast fibrils were examined carefully
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FIG. 1: (Color) (a-c): Confocal microscopy images of
glucagon fibrils with initial concentration 3 mg/mL in aque-
ous buffer (50 mM glycine HCl, pH 2.5) at three consecutive
times: 64, 87 and 126 mins after the onset of fibrillation.
cale bar shows 5 µm. Each circle repre ents a data point
and the red line represents the cumulated tracked positions
of the growing fibril end. (d) Growth of 20 fibrils at the
glucagon concentration of 3 mg/mL. Plateaus correspond to
arrested states while fibrils elongate outside the plateaus. (e)
The average end-to-end-distance squared (
〈
R2ee
〉
) as a func-
tion of fibril length. The solid green line is obtained by fitting
Eq. (1) t combined exp rimental data (red points) from all
glucagon concentrations. The persistence length of fibrils is
returned by the fit as 60± 2µm.
time growth of an individual fibril are shown in Fig. 1(a-
c). The observed growing fibrils are relatively straight
and their persistence length `p can be extr cted by com-
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FIG. 2: (Color) Distributions of stop (a) and growth (b)
durations for fibrils grown at various glucagon concentra-
tions. Straight lines indicate linear fits to the cumulative
data. Three extremely long pauses were removed from the
3 mg/mL sample.
paring the geometric distance between fibril ends Ree to
the fibril length L. For semi-flexible fibrils the average
end-to-end distance is expected to be [16]〈
R2ee
〉
= 2`pL− 2`2p
[
1− e−L/`p
]
, (1)
which agrees extremely well with experimental data
(Fig. 1e). The fitting of equation above to experi-
mental data provides a persistence length `p = 60 ±
2µm. Note that this is of the same order as the per-
sistence length of actin filaments (∼20µm) [17], while
much smaller than the persistence length of microtubules
(∼5, 000µm) [17], and larger than the persistence lengths
of DNA (∼50nm) [18] and amyloid fibrils (0.1–4µm) [19].
By inspecting the time courses of fibril lengths
(Fig. 1d), we find that at all glucagon concentrations
the fibril growth is characterized by periods of growth
(go state) interrupted by periods of stasis (stop state).
The stop states are seen as plateaus, where the fibril does
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FIG. 3: (Color online) Schematic overview of the glucagon growth model showing (upper part) monomer-trimer equilibrium
and (lower part) fibrillation process. Glucagon monomers are in equilibrium with glucagon trimers. Elongation of a fibril is a
two-step process, which can be interrupted by binding of the other oligomer. Fibrils consist of either monomers or trimers but
never a combination of the two. A glucagon trimer (monomer) can bind to a growing fibril end and then dissociate or elongate
the fibril after conformational rearrangement. Filled triangles (circles) symbolize trimers (monomers) bound irreversibly to a
fibril, while hollow triangles (circles) mean unbound trimers (monomers). A glucagon monomer (trimer) can also bind to a
growing fibril end, but in this arrested state it prevents further attachment of glucagon trimers (monomers).
not elongate. As seen in our previous work [15], the dis-
tributions of the stop and go event durations (displayed
in Fig. 2) follow exponential distributions and are fitted
to the form f(x) = a · exp(−k · t). A fibril leaves the go
state at rate kg→s given by growth durations (Fig. 2a)
and leaves the stop state at rate ks→g given by stop du-
rations (Fig. 2b). Both switching rates depend on the
glucagon concentration. The access to kinetic data at
different glucagon concentrations allows us to develop a
model for glucagon’s fibrillation.
The analytical models for the kinetics of fibril growth
were initiated with the Oosawa model [20] and further
elaborated to include hydrolysis and breakage of fib-
rils [21, 22]. Our model is an extension of the Oosawa
model, which includes both monomers and trimers as ba-
sic building blocks for fibrils.
To explain the intermittent fibril growth behavior we
propose a model sketched in Fig. 3. In the bulk solu-
tion glucagon monomers are in equilibrium with glucagon
trimers and these two components give rise to twisted
and non-twisted fibrils, respectively. Successive binding
of glucagon monomers to the twisted fibril end corre-
sponds to the growing state, while binding of trimers to
the twisted fibril end prevents further growth until the
trimer is detached. During this time the twisted fibril
appears to be in the arrested state. The opposite is true
for non-twisted fibrils, which are formed from glucagon
trimers, while glucagon monomers inhibit their growth.
In the mean field approximation, the fibril growth
probability can be expressed in terms of the model rate
constants and compared to the experimentally observed
growth probabilities. The growth probability predicted
by the model is calculated by considering the average
time spent in the growing or arrested state as outlined
below. In a bulk solution glucagon is in equilibrium be-
tween monomers (M) of concentration [G] and trimers
(T) of concentration [G3] with the equilibrium constant
K20 =
[G]3
[G3]
=
k31
k13
(2)
and the total glucagon concentration [Gtot] = [G]+3[G3].
As mentioned before at low (high) glucagon concentra-
tions, i.e., [Gtot]  K0 ([Gtot]  K0), glucagon is pre-
dominantly in the monomer (trimer) state.
For the free growing twisted fibril end it takes on aver-
age the time (k
(M)
b1 [G] +k
(M)
b3 [G3])
−1 before the glucagon
monomer or trimer binds to the tip. This occurs with
probabilities p
(M)
1 or p
(M)
3 respectively, where
p
(M)
1 =
k
(M)
b1 [G]
(k
(M)
b1 [G] + k
(M)
b3 [G3])
= 1− p(M)3 . (3)
If a glucagon monomer is bound to the growing twisted
fibril end, it takes on average the time (k
(M)
u1 +k
(M)
r )−1 for
the glucagon monomer to unbind with probability p
(M)
1u
or to undergo conformational rearrangement and form a
longer fibril with probability p
(M)
1g , where
p
(M)
1u =
k
(M)
u1
k
(M)
r + k
(M)
u1
= 1− p(M)1g . (4)
The average time τ
(M)
1 for a monomer to bind and sub-
sequently either unbind or undergo conformational rear-
4rangement to elongate the twisted fibril is
τ
(M)
1 =
1
(k
(M)
b1 [G] + k
(M)
b3 [G3])
+
1
(k
(M)
u1 + k
(M)
r )
, (5)
while the average time τ
(M)
3 for the binding and unbind-
ing of a glucagon trimer is
τ
(M)
3 =
1
(k
(M)
b1 [G] + k
(M)
b3 [G3])
+
1
k
(M)
u3
. (6)
We define the growth probability p
(M)
G as the expected
average fraction of time the twisted fibril spends in the
growing state:
p
(M)
G =
p
(M)
1 p
(M)
1g τ
(M)
1
p
(M)
1 τ
(M)
1 + p
(M)
3 τ
(M)
3
. (7)
Similarly, we can analyze the dynamics of the grow-
ing non-twisted fibrils, which are formed from glucagon
trimers. The growth probability for non-twisted fibrils is
then
p
(T )
G =
p
(T )
3 p
(T )
3g τ
(T )
3
p
(T )
1 τ
(T )
1 + p
(T )
3 τ
(T )
3
, (8)
where all quantities are defined in analogous way as
above for the twisted fibrils. However, in this case the
role of glucagon monomers and trimers is reversed, i.e.,
in Eqns. (3-6) above one should replace (M) with (T )
and make the 1 ↔ 3 substitutions to obtain the rele-
vant quantities. Since the number of twisted and non-
twisted fibrils is proportional to the number of glucagon
monomers and trimers, respectively, the probability pG
that the randomly chosen fibril is found in the growing
state is
pG =
p
(M)
G [G] + p
(T )
G [G3]
[G] + [G3]
. (9)
It is possible to derive the exact expression for the
growth probability above in terms of the rate constants
and the total glucagon concentration, but for simplic-
ity we present only the asymptotic regimes at low and
high glucagon concentration. At low glucagon concen-
tration, [Gtot]  K0, the majority of glucagon is in the
monomeric state. The slow time scales correspond to
binding of glucagon monomers or trimers to the fibril
ends and the growing probability for twisted fibrils is
p
(M)
G ≈
k
(M)
r
(k
(M)
u1 + k
(M)
r )
[
1− k
(M)
b3
k
(M)
b1
(
[Gtot]
K0
)2]
. (10)
There are only a small number of non-twisted fib-
rils, whose growth is further suppressed by binding of
glucagon monomers
p
(T )
G ≈
k
(T )
b3 k
(T )
r
k
(T )
b1 (k
(T )
u3 + k
(T )
r )
(
[Gtot]
K0
)2
. (11)
The fibril growth probability is thus approximately
plowG ≈
p
(M)
G [G]
([G] + [G3])
, (12)
where [G]/([G] + [G3]) ≈ 1− [Gtot]2/K20 .
At high glucagon concentrations, [Gtot] K0, most of
the glucagon is in the trimeric state. The binding events
are fast because of the large concentration of glucagon
trimers and the slow time steps are the unbinding and
conformational reconfiguration. The growth probability
of non-twisted fibrils is approximately
p
(T )
G ≈
k
(T )
r
(k
(T )
u3 + k
(T )
r )
− k
(T )
b1 k
(T )
r
k
(T )
b3 k
(T )
u1
(
3K0
[Gtot]
)2/3
. (13)
There are only a small number of twisted fibrils, whose
growth is further suppressed by binding of glucagon
trimers
p
(M)
G ≈
k
(M)
b1 k
(M)
r k
(M)
u3
k
(M)
b3 (k
(M)
u1 + k
(M)
r )2
(
3K0
[Gtot]
)2/3
. (14)
The fibril growth probability is thus approximately
phighG ≈
p
(T )
G [G3]
([G] + [G3])
, (15)
where [G3]/([G] + [G3]) ≈ 1− (3K0/[Gtot])2/3.
At intermediate glucagon concentrations, [Gtot] ∼ K0,
there is a mix of twisted and non-twisted fibrils whose
growth is suppressed due to binding of the opposite
glucagon components.
The probability that at any moment a given fibril is
in the growing state can be determined from the exper-
imental switching rates between the stop and go states
as
pG =
ks→g
ks→g + kg→s
. (16)
The measured fibril growth probabilities at different
glucagon concentrations, given by Eq. (16), are displayed
in Fig. 4 as black bars and are seen to qualitatively agree
with the model behavior described above, which is plot-
ted as a full line. We notice that fibril growth probabil-
ities are large at high and low glucagon concentrations,
while they are smaller at intermediate glucagon concen-
trations (∼3 mg/mL). The value of K0 ≈ 1.3 mg/mL ob-
tained from the fit is in accordance with previous studies
of glucagon monomer-trimer equilibrium [6–10]. A pre-
vious study of glucagon fibrillation at a very low concen-
tration (0.25 mg/mL) found the growth probability to be
∼1/4 [15], which is smaller than the growth probabilities
observed in our experiments (Fig. 4). We speculate that
in that study, fibril seeds grown at a higher glucagon con-
centration could bias the distribution of fibrils towards
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FIG. 4: Experimentally measured fibril growth probabili-
ties (black bars) calculated from Eq. (16). The error bars in
experimentally observed growth probabilities are calculated
from uncertainties in the switching rates between the stop
and go states from fitting in Figs. 2(a-b). The grey line
shows a fit of the model in Eq. (9) to the experimental data.
The fit gives K0 ≈ 1.3 mg/mL.
trimeric fibrils and hence result in a lower growth prob-
ability than predicted by our equilibrium model.
The model presented above with two competing fib-
ril morphologies is further supported by the mea-
surements of speeds at which the fibrils are growing
(Fig. 5). The speed distributions seem to have two peaks,
whose magnitudes depend on the glucagon concentra-
tion. At low glucagon concentration the dominant peak
is at ∼100 nm/min, which probably corresponds to the
growing speed of twisted fibrils composed of glucagon
monomers. On the other hand, at large glucagon concen-
tration the dominant peak is at ∼20–30 nm/min, which
probably corresponds to the growing speed of non-twisted
fibrils composed of glucagon trimers.
In conclusion, we present a monomer-trimer model for
glucagon fibrillation and compared it with our experi-
mental data. The model predicts a concentration depen-
dent growth probability, which we test experimentally at
various glucagon concentrations by analyzing the distri-
butions of growth and stasis duration. Our model cap-
tures the short time behavior of growth and pause dura-
tions and reproduce the experimentally observed growth
probability well. The stop-go kinetics observed requires
two contrasting precursor states, one of which elongates
while the other one blocks. Thus, the model might
generically also explain, e.g., fibril growth kinetics for
β-lactoglobulin which exists in a monomer-dimer equilib-
rium, where only the monomer is capable of elongating
fibrils (via a partially unfolded state) [23].
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2.3.1.2 Speed Distribution
Here the speed distribution of all fibrils grown at all concentrations are shown.
Speed distributions were calculated as described in sec. 2.2.6 and are plotted in fig.
2.3.2. Results from different experiments with same initial glucagon concentration
are plotted together.
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Figure 2.3.2: Growth speed distributions of glucagon fibrils shown as histograms
(grey boxes) and a Gaussian kernel (red line) both of width 10 nm/min.
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FIG. 5: (Color online) Growth speed distributions of
glucagon fibrils at various glucagon concentrations (displayed
in top-right corners) are presented as histograms (grey boxes
of width 10 nm/min). With r d solid line we plotted an ap-
proximate distribution, where each experimental data point is
repres nted as a Gaus ian distribution with a fixed standard
variance 10 nm/min.
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